Show simple item record

 
dc.contributorHospital General de Granollers
dc.contributor.authorLuna, Alejandro
dc.contributor.authorPérez-Lamas, Lucía
dc.contributor.authorBoqué-Genovard, Concepción
dc.contributor.authorGiraldo, Pilar
dc.contributor.authorXicoy, Blanca
dc.contributor.authorRuiz Nuño, C.
dc.contributor.authorCortes, Montse
dc.date.accessioned2022-09-13T07:23:20Z
dc.date.available2022-09-13T07:23:20Z
dc.date.issued2022-10
dc.identifier.citationLuna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022 Oct;101:2263-70.
dc.identifier.urihttp://hdl.handle.net/11351/8172
dc.descriptionAsciminib; Inhibitors; Leukemia
dc.description.abstractFailure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.After a median follow-up of 30 months, 34 patients (65%) switched to asciminib due to intolerance and 18 (35%) due to resistance to prior TKIs. Forty-six patients (88%) had received at least 3 prior TKIs. Regarding responses, complete cytogenetic response was achieved or maintained in 74% and 53% for non-PPT and PPT patients, respectively. Deeper responses such as major molecular response and molecular response 4.5 were achieved in 65% and 19% in non-PPT versus 32% and 11% in PPT, respectively. Two patients (4%) harbored the T315I mutation, both PPT.In terms of toxicities, non-PPT displayed 22% grade 3-4 TEAE versus 20% in PPT. Four patients (20% of PPT) suffered from cross-intolerance with asciminib as they did under ponatinib.Our data supports asciminib as a promising alternative in resistant and intolerant non-PPT patients, as well as in intolerant PPT patients; the resistant PPT subset remains as a challenging group in need of further therapeutic options.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesAnnals of Hematology;101
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectInhibidors enzimàtics
dc.subjectLeucèmia - Tractament
dc.subject.meshEnzyme Inhibitors
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subject.mesh/drug therapy
dc.titleReal‑life analysis on safety and efcacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00277-022-04932-6
dc.subject.decsinhibidores enzimáticos
dc.subject.decsleucemia mielogenosa crónica BCR-ABL positiva
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1007/s00277-022-04932-6
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Luna A, Pérez-Lamas L] Hematology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. [Boque C] Institut Catala d’Oncologia, Hospital Duran Y Reynals, L’Hospitalet de Llobregat, Barcelona, Spain. [Giraldo P] Hospital Quirón Zaragoza, Zaragossa, Spain. [Xicoy B] Institut Català d’Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain. [Ruiz Nuño C] Hospital Regional Universitario de Málaga, Málaga, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain
dc.identifier.pmid35997804
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record